Loading
Overweight Or Obesity / Healthy Volunteers / RO7795081 · Phase 1 Trial
ClinicalTrials.gov · August 10, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a Phase 1 clinical trial registration for RO7795081, a novel oral agent under investigation in healthy Chinese adults with overweight or obesity. The study is designed to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics over 26 weeks; no results are currently reported in this registry record.
Phase 1, Interventional, Randomized, Parallel, Double masking, Basic Science purpose. Healthy Volunteers, Overweight or Obesity; age from 18 Years; to 65 Years; accepts healthy volunteers. Intervention: RO7795081. Compared with: Placebo — Placebo Comparator. n = 30. 2 sites: China.
This is a Phase 1 clinical trial registration for RO7795081, a novel oral agent under investigation in healthy Chinese adults with overweight or obesity. The study is designed to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics over 26 weeks; no results are currently reported in this registry record.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
Readers should note this is an early-phase investigation with safety and tolerability as primary endpoints. Results are not yet available in the registry record and must be awaited before any clinical implications can be assessed.
Phase 1 safety and tolerability study of a novel agent in a focused population; no results posted in this registry record.
As stated by the source record.
Quoted from the source exactly as published.
Readers should note this is an early-phase investigation with safety and tolerability as primary endpoints. Results are not yet available in the registry record and must be awaited before any clinical implications can be assessed.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07499050). This is a study registration, not published results. Lead sponsor: Hoffmann-La Roche. Recruitment status: ACTIVE_NOT_RECRUITING. Phase: PHASE1. Study type: INTERVENTIONAL. Enrollment: 30 participants (ESTIMATED). Conditions: Healthy Volunteers, Overweight or Obesity. Interventions: DRUG: RO7795081; DRUG: Placebo. Primary outcome measures: Incidence, Severity, and Causal Relationship to Treatment of Adverse Events , Baseline to Safety Follow-Up (26 weeks); Incidence of Abnormal Clinical Laboratory Test Findings , Baseline to Safety Follow-Up (26 weeks); Incidence of Abnormal Vital Signs , Baseline to Safety Follow-Up (26 weeks); Incidence of Abnormal Electrocardiogram (ECG) Results , Baseline to Safety Follow-Up (26 weeks); Incidence of Abnormal Psychiatry Parameters , Baseline to Safety Follow-Up (26 weeks). Brief summary: This is an investigator- and participant-blind, randomized, placebo-controlled, parallel-group, Phase I study evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple doses of orally administered RO7795081 in otherwise healthy Chinese adult participants with obesity or overweight.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.